In September 2005, Biocheck was acquired in a cash transation by OXIS International (OTCBB: OXIS), a developer of research assays, diagnostics, nutraceutical, and therapeutic products. BioCheck develops and manufactures high-quality enzyme immunoassay test kits for the worldwide biomedical, pharmaceutical, and scientific research markets. Every BioCheck EIA kit is manufactured according to U.S. Food and Drug Administration (FDA) Good Manufacturing Practice standards. At the present time, the company manufactures over 40 EIA test kits, of which 17 have been FDA cleared. The company also has U.S. FDA Certificates to Foreign Governments and Certificates of Exportability for many of its products. BioCheck's EIA kits have also been registered in Brazil, India, Italy, Taiwan, Turkey, and the United Kingdom. The firm also work with distributors to deliver products to countries in Central and South America, Europe, the Middle East, and Asia. BioCheck is currently working with leading-edge biopharmaceutical companies to take advantage of advances in genomics in order to develop novel test kits that improve earlier and accurate detection of diseases.
